0
Business
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?
May 2, 2026
Scroll
Posted 2 hours ago by
Regeneron is seeing double-digit revenue growth and has more than 50 therapies in its pipeline, making it a good long-term investment.
The Motley Fool
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: lean left
People's Voices (0)
Leave a comment
0/500
Note: Comments are moderated. Please keep it civil. Max 3 comments per day.